Ceapro (TSXV:CZO) Asset Impairment Charge : C$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Ceapro Asset Impairment Charge?

Ceapro's Asset Impairment Charge for the three months ended in Dec. 2023 was C$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil.

Ceapro Asset Impairment Charge Historical Data

The historical data trend for Ceapro's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ceapro Asset Impairment Charge Chart

Ceapro Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Ceapro Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Ceapro Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Ceapro Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Ceapro's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Ceapro (TSXV:CZO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ceapro Inc (TSXV:CZO) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

CRPOF:USA

Address

7824-51 Avenue NW, Edmonton, AB, CAN, T6E 6W2

Website

https://www.ceapro.com

Ceapro Inc is engaged in the development and marketing of various health and wellness products and technology relating to plant extracts. Its operating segment is the active ingredient product technology industry which involves the development of proprietary extraction technologies and the application of these technologies to the production and development and commercialization of active ingredients derived from oats and other renewable plant resources for healthcare and cosmetic industries. Active ingredients produced include oat beta glucan and avenanthramides. The group derives revenue from the U.S., Germany, China, Canada and other countries, of which prime revenue is generated from the U.S.

Ceapro (TSXV:CZO) Headlines

No Headlines